Home » Stocks » ESPR

Esperion Therapeutics, Inc. (ESPR)

Stock Price: $27.39 USD -0.29 (-1.05%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $28.10 +0.71 (2.59%) Feb 26, 6:57 PM
Market Cap 765.35M
Revenue (ttm) 227.55M
Net Income (ttm) -143.55M
Shares Out 27.47M
EPS (ttm) -5.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $27.39
Previous Close $27.68
Change ($) -0.29
Change (%) -1.05%
Day's Open 27.89
Day's Range 26.23 - 28.24
Day's Volume 704,665
52-Week Range 23.90 - 56.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.

Zacks Investment Research - 4 days ago

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for...

Benzinga - 4 days ago

Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 72.12% over the past year to ...

GlobeNewsWire - 4 days ago

ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the fourth quarter and full year ended December 3...

GlobeNewsWire - 2 weeks ago

ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. fina...

Seeking Alpha - 4 weeks ago

Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly leveraged to Covid-reopening, but unlike many indus...

GlobeNewsWire - 4 weeks ago

ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion's Board of Directors granted 10 ne...

Benzinga - 1 month ago

Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Ho...

Other stocks mentioned: NVS, VBIV
Zacks Investment Research - 1 month ago

Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.

The Motley Fool - 1 month ago

The company gave a sneak peek into its fourth-quarter financial results.

GlobeNewsWire - 1 month ago

– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million –

GlobeNewsWire - 2 months ago

ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annua...

Benzinga - 2 months ago

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Com...

Other stocks mentioned: BLRX, HTBX
GlobeNewsWire - 2 months ago

- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients -

Business Wire - 2 months ago

MUNICH & ANN ARBOR, Mich.--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo') and Esperion Therapeutics (NASDAQ: ESPR) announced today Swissmedic approval for NILEMDO®▼ ...

GlobeNewsWire - 2 months ago

ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating ...

Zacks Investment Research - 2 months ago

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 -

GlobeNewsWire - 3 months ago

ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated No...

GlobeNewsWire - 3 months ago

ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate pri...

Seeking Alpha - 3 months ago

Esperion's approved product bempedoic acid is a non-statin, lipid-lowering drug with proven efficacy. However, high burn rate, poor uptake, and coronavirus have all dampened the prospects of t...

GlobeNewsWire - 3 months ago

ANN ARBOR, Mich., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion's Board of Directors granted 33,66...

Zacks Investment Research - 3 months ago

Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.

Seeking Alpha - 3 months ago

Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.78% and 4.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Benzinga - 3 months ago

Shares of Esperion Therapeutics (NASDAQ:ESPR) fell 2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 21.83% over the past year to ($3....

GlobeNewsWire - 3 months ago

– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL ® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets –

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during t...

Zacks Investment Research - 4 months ago

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets o...

GlobeNewsWire - 4 months ago

ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed...

Zacks Investment Research - 5 months ago

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 5 months ago

ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during ...

GlobeNewsWire - 6 months ago

ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL® (bempedoic ac...

The Motley Fool - 6 months ago

Sales of these recently launched products could make a big difference for the companies behind them.

Other stocks mentioned: BMY, IMMU
Zacks Investment Research - 6 months ago

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.

Seeking Alpha - 6 months ago

Esperion Therapeutics, Inc. (ESPR) CEO Tim Mayleben on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 102.82% and -0.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 6 months ago

– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue –

GlobeNewsWire - 6 months ago

ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets...

Investors Business Daily - 7 months ago

Esperion Therapeutics sees its Relative Strength Rating reach the 80-plus level. The post Esperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold appeared first on In...

GlobeNewsWire - 7 months ago

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-da...

Seeking Alpha - 8 months ago

Esperion Therapeutics: An Easy Double, Maybe A Lot More

GlobeNewsWire - 8 months ago

ANN ARBOR, Mich., June 22, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (...

GlobeNewsWire - 8 months ago

ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American...

GlobeNewsWire - 8 months ago

ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess ne...

GlobeNewsWire - 8 months ago

ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fi...

Zacks Investment Research - 8 months ago

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 8 months ago

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – –  Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access ...

About ESPR

Esperion Therapeutics, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2013
CEO
Timothy Mayleben
Employees
479
Stock Exchange
NASDAQ
Ticker Symbol
ESPR
Full Company Profile

Financial Performance

In 2020, ESPR's revenue was $227.55 million, an increase of 53.37% compared to the previous year's $148.36 million. Losses were -$143.55 million, 47.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is 69.10, which is an increase of 152.28% from the latest price.

Price Target
$69.10
(152.28% upside)
Analyst Consensus: Buy